loxo-338
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2021 (NCT05024045)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05024045 | Phase 1 | Sep 30, 2021 | Eli Lilly, Loxo Oncology |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2021 |
| Loxo Oncology | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1